Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Renal Cell Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT01727336
What this trial is testing

Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma

Who this might be right for
Advanced Renal Cell Carcinoma
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 160
Testing effectiveness (Phase 2)Looking for participantsNCT06682793
What this trial is testing

Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Who this might be right for
Solid Tumor, AdultColorectal CancerNon-Small Cell Lung+14 more
A2 Biotherapeutics Inc. 240
Large-scale testing (Phase 3)Study completedNCT00942331
What this trial is testing

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Who this might be right for
Advanced Urothelial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Prostate Carcinoma+10 more
National Cancer Institute (NCI) 506
Testing effectiveness (Phase 2)Looking for participantsNCT05944237
What this trial is testing

HTL0039732 in Participants With Advanced Solid Tumours

Who this might be right for
NeoplasmsProstatic Neoplasms, Castration-ResistantStomach Neoplasms+11 more
Cancer Research UK 150
Not applicableStudy completedNCT00836745
What this trial is testing

Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent

Who this might be right for
Renal Cell Carcinoma
Pfizer 36
Testing effectiveness (Phase 2)Study completedNCT00609401
What this trial is testing

Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)

Who this might be right for
Metastatic DiseaseRenal Cell Carcinoma
Italian Trial in Medical Oncology 90
Testing effectiveness (Phase 2)Study completedNCT02917772
What this trial is testing

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma

Who this might be right for
Carcinoma, Renal CellClear-cell Metastatic Renal Cell Carcinoma
AIO-Studien-gGmbH 200
Not applicableStudy completedNCT00477919
What this trial is testing

E-MOSAIC Electronic Tool to Monitor Symptoms

Who this might be right for
Cancer
Swiss Cancer Institute 264
Early research (Phase 1)Study completedNCT01307267
What this trial is testing

PF-05082566 As A Single Agent And In Combination With Rituximab

Who this might be right for
Lymphoma, Non-HodgkinLymphoma, FollicularLymphoma, Large B-Cell, Diffuse+4 more
Pfizer 190
Early research (Phase 1)Ended earlyNCT00816686
What this trial is testing

The Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer

Who this might be right for
Carcinoma, Renal CellKidney NeoplasmsKidney Diseases
Astellas Pharma Inc 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT05468697
What this trial is testing

Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 60
Early research (Phase 1)Looking for participantsNCT07128680
What this trial is testing

Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer

Who this might be right for
Advanced Clear Cell Renal Cell CarcinomaAdvanced Sarcomatoid Renal Cell CarcinomaMetastatic Clear Cell Renal Cell Carcinoma+3 more
City of Hope Medical Center 33
Testing effectiveness (Phase 2)Study completedNCT00126503
What this trial is testing

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Who this might be right for
Chromophobe Renal Cell CarcinomaClear Cell Renal Cell CarcinomaPapillary Renal Cell Carcinoma+3 more
National Cancer Institute (NCI) 73
Testing effectiveness (Phase 2)Looking for participantsNCT07175480
What this trial is testing

PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk

Who this might be right for
Renal Cell Carcinoma (RCC)Metastatic Renal Cell Carcinoma (mRCC)
Jinling Hospital, China 30
Not applicableStudy completedNCT02370290
What this trial is testing

Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer

Who this might be right for
Renal Cell Carcinoma
University of Southern California 74
Testing effectiveness (Phase 2)Looking for participantsNCT05361720
What this trial is testing

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Who this might be right for
Advanced Clear Cell Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8+1 more
Vanderbilt-Ingram Cancer Center 54
Large-scale testing (Phase 3)Study completedNCT02426125
What this trial is testing

Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer

Who this might be right for
Urothelial Carcinoma
Eli Lilly and Company 530
Early research (Phase 1)Active Not RecruitingNCT04707248
What this trial is testing

DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Who this might be right for
Renal Cell CarcinomaOvarian Tumor
Daiichi Sankyo 179
Testing effectiveness (Phase 2)Ended earlyNCT00684996
What this trial is testing

Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Who this might be right for
Recurrent Renal Cell CancerRenal Cell CarcinomaStage III Renal Cell Cancer+1 more
National Cancer Institute (NCI) 5
Large-scale testing (Phase 3)Active Not RecruitingNCT05043090
What this trial is testing

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Who this might be right for
Papillary Renal Cell Carcinoma
AstraZeneca 148
Next Page